Our top pick for
Ovid Therapeutics Inc is a biotechnology business based in the US. Ovid Therapeutics shares (OVID) are listed on the NASDAQ and all prices are listed in US Dollars. Ovid Therapeutics employs 60 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$3.62|
|52-week range||$2.25 - $6.43|
|50-day moving average||$3.49|
|200-day moving average||$3.78|
|Wall St. target price||$4.75|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$1.81|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-15)||0.56%|
|1 month (2021-09-22)||6.47%|
|3 months (2021-07-22)||-5.24%|
|6 months (2021-04-22)||-1.09%|
|1 year (2020-10-22)||-32.59%|
|2 years (2019-10-22)||62.33%|
|3 years (2018-10-22)||5.99|
|5 years (2016-10-18)||N/A|
Valuing Ovid Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Ovid Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Ovid Therapeutics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 2x. In other words, Ovid Therapeutics shares trade at around 2x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Ovid Therapeutics's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $132.7 million.
The EBITDA is a measure of a Ovid Therapeutics's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$221 million|
|Operating margin TTM||59.93%|
|Gross profit TTM||$-48,020,415|
|Return on assets TTM||62.87%|
|Return on equity TTM||102.67%|
|Market capitalisation||$244.6 million|
TTM: trailing 12 months
There are currently 1.0 million Ovid Therapeutics shares held short by investors – that's known as Ovid Therapeutics's "short interest". This figure is 12.9% down from 1.2 million last month.
There are a few different ways that this level of interest in shorting Ovid Therapeutics shares can be evaluated.
Ovid Therapeutics's "short interest ratio" (SIR) is the quantity of Ovid Therapeutics shares currently shorted divided by the average quantity of Ovid Therapeutics shares traded daily (recently around 205028.76984127). Ovid Therapeutics's SIR currently stands at 5.04. In other words for every 100,000 Ovid Therapeutics shares traded daily on the market, roughly 5040 shares are currently held short.
However Ovid Therapeutics's short interest can also be evaluated against the total number of Ovid Therapeutics shares, or, against the total number of tradable Ovid Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Ovid Therapeutics's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Ovid Therapeutics shares in existence, roughly 20 shares are currently held short) or 0.0288% of the tradable shares (for every 100,000 tradable Ovid Therapeutics shares, roughly 29 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Ovid Therapeutics.
Find out more about how you can short Ovid Therapeutics stock.
We're not expecting Ovid Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, Ovid Therapeutics's shares have ranged in value from as little as $2.25 up to $6.431. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Ovid Therapeutics's is 1.7514. This would suggest that Ovid Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Ovid Therapeutics Inc. , a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase III clinical trial for the treatment of angelman syndrome in adults; and completed Phase II clinical trial for the treatment of fragile X syndrome in adolescent and young male adults. It is also developing OV935, a drug candidate, which has completed Phase II clinical trial for the treatment of cyclin-dependent kinase-like 5 deficiency disorder and dravet syndrome. In addition, the company undertakes research programs exploring OV329 in infantile spasm/rare epilepsies; OV882 as a short hairpin RNA gene therapy for the treatment of angelman syndrome; and OV815, a gene modulation therapy for the treatment of kinesin-family of proteins associated neurological disorder. Ovid Therapeutics Inc. has a collaboration agreement with Takeda Pharmaceutical Company Limited; a license agreement with H.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.